TY - JOUR
T1 - Tumor necrosis factor (TNF)-α, soluble TNF receptors and endometrial cancer risk
T2 - The EPIC study
AU - Dossus, Laure
AU - Becker, Susen
AU - Rinaldi, Sabina
AU - Lukanova, Annekatrin
AU - Tjønneland, Anne
AU - Olsen, Anja
AU - Overvad, Kim
AU - Chabbert-Buffet, Nathalie
AU - Boutron-Ruault, Marie Christine
AU - Clavel-Chapelon, Françoise
AU - Teucher, Birgit
AU - Chang-Claude, Jenny
AU - Pischon, Tobias
AU - Boeing, Heiner
AU - Trichopoulou, Antonia
AU - Benetou, Vasiliki
AU - Valanou, Elisavet
AU - Palli, Domenico
AU - Sieri, Sabina
AU - Tumino, Rosario
AU - Sacerdote, Carlotta
AU - Galasso, Rocco
AU - Redondo, Maria Luísa
AU - Bonet, Catalina Bonet
AU - Molina-Montes, Esther
AU - Altzibar, Jone M.
AU - Chirlaque, Maria Dolores
AU - Ardanaz, Eva
AU - Bas Bueno-De-Mesquita, H.
AU - Van Duijnhoven, Fränzel J.B.
AU - Peeters, Petra H.M.
AU - Charlotte Onland-Moret, N.
AU - Lundin, Eva
AU - Idahl, Annika
AU - Khaw, Kay Tee
AU - Wareham, Nicholas
AU - Allen, Naomi
AU - Romieu, Isabelle
AU - Fedirko, Veronika
AU - Hainaut, Pierre
AU - Romaguera, Dora
AU - Norat, Teresa
AU - Riboli, Elio
AU - Kaaks, Rudolf
PY - 2011/10/15
Y1 - 2011/10/15
N2 - Chronic inflammation has been hypothesized to play a role in endometrial cancer development. Tumor necrosis factor-α (TNF-α), one of the major pro-inflammatory cytokines, has also been implicated in endometrial physiology. We conducted a case-control study nested within the European prospective investigation into cancer and nutrition (EPIC) to examine the association of TNF-α and its two soluble receptors (sTNFR1 and sTNFR2) with endometrial cancer risk. Two-hundred-seventy cases and 518 matched controls were analyzed using conditional logistic regression. All statistical tests were two-sided. We observed an increased risk of endometrial cancer among women in the highest versus lowest quartile of TNF-α (odds ratio [OR]: 1.73, 95% CI: 1.09-2.73, Ptrend = 0.01), sTNFR1 (OR: 1.68, 95% CI: 0.99-2.86, Ptrend = 0.07) and sTNFR2 (OR: 1.53, 95%CI: 0.92-2.55, P trend = 0.03) after adjustment for body-mass-index, parity, age at menopause and previous postmenopausal hormone therapy use. Further adjustments for estrogens and C-peptide had minor effect on risk estimates. Our data show that elevated prediagnostic concentrations of TNF-α and its soluble receptors are related to a higher risk of endometrial cancer, particularly strong in women diagnosed within 2 years of blood donation. This is the first study of its kind and therefore deserves replication in further prospective studies.
AB - Chronic inflammation has been hypothesized to play a role in endometrial cancer development. Tumor necrosis factor-α (TNF-α), one of the major pro-inflammatory cytokines, has also been implicated in endometrial physiology. We conducted a case-control study nested within the European prospective investigation into cancer and nutrition (EPIC) to examine the association of TNF-α and its two soluble receptors (sTNFR1 and sTNFR2) with endometrial cancer risk. Two-hundred-seventy cases and 518 matched controls were analyzed using conditional logistic regression. All statistical tests were two-sided. We observed an increased risk of endometrial cancer among women in the highest versus lowest quartile of TNF-α (odds ratio [OR]: 1.73, 95% CI: 1.09-2.73, Ptrend = 0.01), sTNFR1 (OR: 1.68, 95% CI: 0.99-2.86, Ptrend = 0.07) and sTNFR2 (OR: 1.53, 95%CI: 0.92-2.55, P trend = 0.03) after adjustment for body-mass-index, parity, age at menopause and previous postmenopausal hormone therapy use. Further adjustments for estrogens and C-peptide had minor effect on risk estimates. Our data show that elevated prediagnostic concentrations of TNF-α and its soluble receptors are related to a higher risk of endometrial cancer, particularly strong in women diagnosed within 2 years of blood donation. This is the first study of its kind and therefore deserves replication in further prospective studies.
KW - endometrial cancer
KW - inflammation
KW - prospective
KW - soluble TNF receptors
KW - tumor necrosis factor (TNF)-α
UR - https://www.scopus.com/pages/publications/80052014085
U2 - 10.1002/ijc.25840
DO - 10.1002/ijc.25840
M3 - Article
C2 - 21154749
AN - SCOPUS:80052014085
SN - 0020-7136
VL - 129
SP - 2032
EP - 2037
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 8
ER -